Gujarat Themis Biosyn LimitedGUJTHEMCorporate

Pharmaceuticals Latest results: Jun 2026 12 quarters of data

₹373.40

MCap ₹4,860 Cr · P/E 101.1

Gujarat Themis Biosyn Limited — Stock analysis & AI research Gujarat Themis Biosyn Limited — Multibagger AI analysis Gujarat Themis Biosyn Limited — Seasonality — best & worst months Gujarat Themis Biosyn Limited — Technical indicators & charts Gujarat Themis Biosyn Limited — Technical setup — score, trend, support & resistance Gujarat Themis Biosyn Limited — Live exchange announcements

📋 High Operating Margin Stocks 📋 High Interest Coverage Stocks 🏭 Pharma sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹44 Cr

Sales · Jun 2026

+21.6% YoY

₹21 Cr

Operating Profit · Jun 2026

+48.5% YoY

47.5%

OPM % · Jun 2026

+22.1% YoY

₹11 Cr

Net Profit · Jun 2026

+23.0% YoY

₹1.02

EPS · Jun 2026

+22.9% YoY

📝 Gujarat Themis Biosyn Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Gujarat Themis Biosyn Limited reported revenue of ₹44 crore for the quarter ended June 2026 (Q1 FY27), up 21.6% from ₹36 crore in the same quarter last year, and down 0.5% sequentially over the March 2026 quarter.

Net profit rose 23.0% year-on-year to ₹11 crore, from ₹9 crore. Earnings per share (EPS) came in at ₹1.02.

Operating profit stood at ₹21 crore — an operating margin (OPM) of 47.5%, compared with 38.9% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Gujarat Themis Biosyn Limited posted revenue of ₹165 crore, a growth of 8.6% over FY25, with a net profit of ₹46 crore (down 6.1% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹173 crore with a net profit of ₹48 crore.

Valuation snapshot

At the current price of ₹373.40, GUJTHEM has a market capitalisation of ₹4,860 crore and a trailing P/E of about 101.1.

Within the Pharmaceuticals industry, it is the 3rd-largest of the 82 companies we track by market value.

Shareholding pattern

As of Aug 2026, promoters held 59.33%, foreign institutional investors (FIIs) 4.93%, domestic institutional investors (DIIs) 13.79%, public shareholders 21.95% of Gujarat Themis Biosyn Limited.

Promoter holding slipped from 70.86% to 59.33% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹4,860 Cr

Current Price ?

₹373.4

P/E ?

101.11above ind

Industry P/E ?

22.40

P/B ?

N/A

P/S ?

28.13

P/FCF ?

N/A

Enterprise Value ?

N/A

EV/EBITDA ?

N/A

PEG ?

N/A

Earnings Yield ?

1.0%

Dividend Yield ?

N/A

Profitability & Returns

Sales (TTM) ?

₹173 Cr

OPM ?

47.3%

Profit after tax (TTM) ?

₹48 Cr

EPS (TTM) ?

₹3.69

ROCE ?

N/A

ROE ?

N/A

ROA ?

N/A

Growth

Sales — latest qtr ?

₹44 Cr

PAT — latest qtr ?

₹11 Cr

YoY qtr sales growth ?

21.6%

YoY qtr profit growth ?

23.0%

Sales growth (3y) ?

N/A

Sales growth (5y) ?

N/A

Profit growth (3y) ?

N/A

Profit growth (5y) ?

N/A

Financial Health

Debt ?

N/A

Debt to Equity ?

N/A

Interest Coverage ?

20.7

Current Ratio ?

N/A

Ownership

Promoter holding ?

59.33%

Change in promoter holding ?

-11.53%

Pledged percentage ?

N/A

Market

Return 3 months ?

1.0%

Return 6 months ?

17.0%

🗓️ Quarterly results (12 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	YoY %	QoQ %
Sales	40	39	42	39	35	40	38	36	42	43	44	44	+21.6%	-0.5%
Operating Profit	17	18	21	19	15	19	16	14	21	21	19	21	+48.5%	+9.4%
Other Income	1	1	1	1	0	0	1	0	1	0	1	0	—	-86.8%
Interest	0	0	0	0	0	0	0	0	0	1	2	2	—	-10.7%
Depreciation	1	1	1	1	1	2	1	2	3	4	4	4	+98.6%	-0.7%
Profit Before Tax	17	18	21	18	14	17	16	12	19	17	14	15	+26.4%	+8.3%
Net Profit	13	13	16	13	11	13	12	9	14	12	11	11	+23.0%	+0.6%
EPS	1.15	1.79	1.46	1.21	0.97	1.19	1.10	0.83	1.31	1.14	1.00	1.02	+22.9%	+2.0%
OPM %	42.5%	45.7%	50.0%	48.7%	42.9%	47.5%	42.1%	38.9%	50.0%	48.8%	43.2%	47.5%	+22.1%	+10.0%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric	FY25	FY26	TTM	YoY %
Sales	₹152 Cr	₹165 Cr	₹173 Cr	+8.6%
Operating Profit	₹69 Cr	₹75 Cr	₹82 Cr	+8.7%
OPM %	45.39%	45.45%	47.34%	+0.1%
NPM %	32.24%	27.88%	27.82%	-13.5%
Other Income	₹2 Cr	₹2 Cr	₹2 Cr	+0.0%
Depreciation	₹5 Cr	₹13 Cr	₹15 Cr	+160.0%
Interest	₹0 Cr	₹3 Cr	₹5 Cr	—
EBIT	₹64 Cr	₹62 Cr	₹67 Cr	-3.1%
PBT	₹65 Cr	₹62 Cr	₹65 Cr	-4.6%
Tax	—	—	₹4 Cr	—
Net Profit	₹49 Cr	₹46 Cr	₹48 Cr	-6.1%
EPS	₹4.47	₹4.28	₹4.47	-4.3%
Material Cost	—	—	₹8 Cr	—
Employee Cost	—	—	₹5 Cr	—
Extraordinary Items	—	—	—	—

👥 Shareholding (latest 2 periods)

Metric	Jun 2026	Aug 2026	% Chg
Promoters	70.86%	59.33%	-16.3%
FIIs	1.77%	4.93%	+178.5%
DIIs	1.18%	13.79%	+1068.6%
Public	26.19%	21.95%	-16.2%
No. of Shareholders	27,010	26,899	-0.4%

⚖️ Peer comparison

Industry: Pharmaceuticals · top 25 of 82 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	SUDEEPPHRM Sudeep Pharma	₹1,033.30	11,671	63.3	675	184	34.6%	27.3%	—	—	26.6%	30.9%
2	SPARC Sun Pharma	₹185.08	6,006	3.8	1,909	1,584	84.7%	83.0%	2512.3%	553.9%	314.1%	59.9%
3	GUJTHEM Gujarat Themis	₹412.60	5,370	92.3	173	48	47.3%	27.8%	8.6%	-6.1%	21.6%	23.0%
4	539997 Kwality Pharmaceuticals	₹2,652.10	3,525	34.0	553	81	24.4%	14.6%	35.7%	71.8%	46.3%	113.5%
5	524632 Shukra Pharmaceuticals	₹80.95	2,403	99.9	75	36	65.0%	48.2%	74.0%	130.1%	336.4%	1359.2%
6	FERMENTA Fermenta Biotech	₹475.00	1,362	21.4	501	64	18.9%	12.7%	—	—	-17.9%	-30.6%
7	506414 Fermenta Biotech	₹552.60	1,313	27.2	511	59	17.6%	11.5%	11.9%	-6.6%	-10.4%	-56.7%
8	AHCL Anlon Healthcare	₹20.20	1,074	—	—	—	—	—	—	—	163.0%	133.3%
9	541096 Bharat Parenterals	₹1,525.00	1,062	—	323	-30	3.3%	-9.3%	1.5%	37.5%	-19.2%	-309.6%
10	540737 Shree Ganesh	₹796.30	855	66.2	99	15	31.4%	15.6%	0.7%	-23.0%	-41.8%	-67.5%
11	AMANTA Amanta Healthcare	₹197.75	768	52.5	291	15	20.4%	5.0%	—	—	5.4%	-5.6%
12	539730 Fredun Pharmaceuticals	₹827.85	611	10.3	747	44	14.7%	5.9%	40.1%	90.0%	90.2%	88.1%
13	500422 Transchem Ltd-$	₹38.00	474	10.8	—	4	—	—	-100.0%	-17.8%	-100.0%	186.3%
14	HALEOSLABS Haleos Labs	₹1,525.00	461	21.0	324	15	12.6%	4.7%	-3.2%	-4.9%	-11.6%	-58.0%
15	524731 Jenburkt Pharmaceuticals	₹865.75	404	11.6	170	33	23.6%	19.4%	11.8%	6.1%	-1.4%	-26.4%
16	543616 Trident Lifeline	₹279.85	364	14.0	134	24	24.6%	17.9%	—	—	42.6%	44.2%
17	512600 Astal Laboratories	₹75.00	308	32.3	170	10	8.8%	5.7%	142.9%	-9.0%	56.0%	77.4%
18	524828 BDH Industries	₹336.80	300	16.6	100	12	15.3%	11.7%	44.3%	16.6%	20.2%	48.8%
19	500009 Ambalal Sarabhai	₹38.73	297	21.9	206	14	7.1%	6.6%	3.1%	261.1%	8.0%	-51.6%
20	532039 Zenotech Laboratories	₹64.90	263	—	45	-3	17.0%	-5.6%	1.3%	-119.2%	10.1%	-146.0%
21	531739 Gennex Laboratories	₹13.87	255	19.0	183	21	14.4%	11.3%	24.9%	15.5%	16.6%	-6.9%
22	524790 Everest Organics	₹159.20	252	29.4	191	5	10.3%	2.8%	23.0%	527.7%	-10.0%	-21.1%
23	530163 Kerala Ayurveda	₹310.20	225	—	125	-26	-14.9%	-20.8%	9.0%	-16.8%	-21.3%	-477.8%
24	531569 Sanjivani Paranteral	₹199.95	214	32.7	66	7	15.3%	11.3%	-7.6%	-14.4%	8.8%	32.7%
25	524636 Oxygenta Pharmaceutical	₹32.25	195	—	135	-14	-5.9%	-10.1%	3.3%	-70.8%	144.5%	65.6%

❓ Frequently asked questions

What was Gujarat Themis Biosyn Limited's revenue in Q1 FY27?

What was Gujarat Themis Biosyn Limited's net profit in Q1 FY27?